The therapeutic community is excited with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s demonstrating significant potential in clinical trials for managing obesity. Unlike some available weight loss approaches, retatrutide appears to provide a greater substantial reduction in body weight and enhance metabolic heal